Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.
Company Details
- Employees
- 26
- Founded
- -
- Address
- 20400 Century Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- seraxis.com
- Keywords
- Cell therapy, Regenerative medicine, Stem cells, Type 1 Diabetes, Organ replacement, Functional endocrine pancreas, Off-the-shelf implants.
- HQ
- Germantown, Maryland
Seraxis Questions
Seraxis's website is seraxis.com
Seraxis's LinkedIn profile is https://www.linkedin.com/company/seraxis
Seraxis has
26 employees.
View email and phone details for 26
employees at Seraxis.
Seraxis's industry is
Biotechnology Research
Seraxis's top competitors are
Nextcell Pharma Ab,
Altucell,
Betalin Therapeutics Ltd.,
Osiris Therapeutics,
Pharmacyte Biotech,
Unicyte Ag,
Orgenesis Inc.,
Sernova,
Viacyte,
Beta-O2 Technologies Ltd..
Seraxis's categories are Biotechnology Research
Seraxis's founding year is 2013
